Scientific Article
previous document  unige:24698  next document
add to browser collection
Title

The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme

Authors
Zhu, H.
Woolfenden, S.
Bronson, R. T.
Jaffer, Z. M.
Barluenga, S.
Rubenstein, A. E.
Chen, R.
show hidden authors show all authors [1 - 9]
Published in Molecular Cancer Therapeutics. 2010, vol. 9, no. 9, p. 2618-2626
Abstract Glioblastoma multiforme (GBM) has an abysmal prognosis. We now know that the epidermal growth factor receptor (EGFR) signaling pathway and the loss of function of the tumor suppressor genes p16Ink4a/p19ARF and PTEN play a crucial role in GBM pathogenesis: initiating the early stages of tumor development, sustaining tumor growth, promoting infiltration, and mediating resistance to therapy. We have recently shown that this genetic combination is sufficient to promote the development of GBM in adult mice. Therapeutic agents raised against single targets of the EGFR signaling pathway have proven rather inefficient in GBM therapy, showing the need for combinatorial therapeutic approaches. An effective strategy for concurrent disruption of multiple signaling pathways is via the inhibition of the molecular chaperone heat shock protein 90 (Hsp90). Hsp90 inhibition leads to the degradation of so-called client proteins, many of which are key effectors of GBM pathogenesis. NXD30001 is a novel second generation Hsp90 inhibitor that shows improved pharmacokinetic parameters. Here we show that NXD30001 is a potent inhibitor of GBM cell growth in vitro consistent with its capacity to inhibit several key targets and regulators of GBM biology. We also show the efficacy of NXD30001 in vivo in an EGFR-driven genetically engineered mouse model of GBM. Our findings establish that the Hsp90 inhibitor NXD30001 is a therapeutically multivalent molecule, whose actions strike GBM at the core of its drivers of tumorigenesis and represent a compelling rationale for its use in GBM treatment.
Identifiers
Full text
Citation
(ISO format)
ZHU, H. et al. The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme. In: Molecular Cancer Therapeutics, 2010, vol. 9, n° 9, p. 2618-2626. https://archive-ouverte.unige.ch/unige:24698

185 hits

1 download

Update

Deposited on : 2012-12-18

Export document
Format :
Citation style :